Literature DB >> 28786071

Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010-2015.

Ping Zhang1, Hong-Xiang Chen2, Jian-Jun Xing1, Zhao Jin1, Feng Hu1, Teng-Long Li1, Xiao-Yong Zhou3.   

Abstract

Erythroderma with complicated etiology is one of the severe skin diseases and has high mortality, of which the incidence was 0.5‰-1.5‰ in skin diseases. Erythrodermic psoriasis (EP) is the commonest type of erythroderma. In addition, there are drug-induced erythroderma, erythroderma secondary to preexisting dermatoses, malignancy-related erythroderma, and idiopathic erythroderma of unknown etiology. Erythroderma of different etiologies has various clinical manifestations, resulting in relevant curative effects and outcomes. In this article, we retrospectively investigated 205 erythroderma patients about clinical symptoms, auxiliary examination and treatments, and evaluated the efficacy and prognosis. There were 84 cases of EP among 205 patients, 10 cases of erythroderma caused by specific drugs, 77 cases of erythroderma secondary to preexisting dermatoses (excluding psoriasis), 7 cases of erythroderma patients suffering from malignancy and 27 cases with unknown causes. We concluded that the etiology of male patients in different age groups had significant difference. The incidence of EP was the highest among all types. The EP was commonly accompanied with hypoproteinemia, and changed into psoriasis vulgaris after treatment. Drug-induced erythroderma was commonly accompanied with fever, and mostly cured by systematic steroid therapy. For erythroderma secondary to preexisting dermatoses, the original dermatoses must be actively treated to achieve a satisfying prognosis. Erythroderma with malignancy or unknown causes had long-term duration, poor response to the treatment, and high potential to relapse. Therefore, clarifying the etiology, providing an appropiate and individual regimen, and regular follow-up are crucial for the successful treatment of erythroderma with unknown causes.

Entities:  

Keywords:  clinical manifestations; erythroderma; erythrodermic psoriasis; retrospectively investigation

Mesh:

Year:  2017        PMID: 28786071     DOI: 10.1007/s11596-017-1773-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  19 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Erythroderma: clinical and laboratory follow up of 66 Mexican patients.

Authors:  Paula Torres-Camacho; Andres Tirado-Sanchez; Rosa Maria Ponce-Olivera
Journal:  Indian J Dermatol Venereol Leprol       Date:  2009 Sep-Oct       Impact factor: 2.545

Review 3.  Novel psoriasis therapies and patient outcomes, part 1: topical medications.

Authors:  Meghan A Feely; Barry L Smith; Jeffrey M Weinberg
Journal:  Cutis       Date:  2015-03

4.  Erythroderma: a clinical study of 97 cases.

Authors:  Maryam Akhyani; Zahra S Ghodsi; Siavash Toosi; Hossein Dabbaghian
Journal:  BMC Dermatol       Date:  2005-05-09

Review 5.  A review of the diagnosis and management of erythroderma (generalized red skin).

Authors:  Nisha Mistry; Ambika Gupta; Afsaneh Alavi; R Gary Sibbald
Journal:  Adv Skin Wound Care       Date:  2015-05       Impact factor: 2.347

6.  The incidence of erythroderma: a survey among all dermatologists in The Netherlands.

Authors:  V Sigurdsson; P H Steegmans; W A van Vloten
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

7.  Exfoliative dermatitis: patterns of clinical presentation in a tropical rural and suburban dermatology practice in Nigeria.

Authors:  Taofik A T Salami; Odigie Enahoro Oziegbe; Henry Omeife
Journal:  Int J Dermatol       Date:  2012-09       Impact factor: 2.736

8.  High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study.

Authors:  Salam Itani; Asma Arabi; Dana Harb; Diana Hamzeh; Abdul-Ghani Kibbi
Journal:  Int J Dermatol       Date:  2016-01-08       Impact factor: 2.736

9.  Causes and features of erythroderma.

Authors:  Grace F L Tan; Yan Ling Kong; Andy S L Tan; Hong Liang Tey
Journal:  Ann Acad Med Singap       Date:  2014-08       Impact factor: 2.473

10.  Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control Study.

Authors:  Udayakumar Praveenkumar; Satyaki Ganguly; Lopamudra Ray; Sunil Kumar Nanda; Sheela Kuruvila
Journal:  J Clin Diagn Res       Date:  2016-02-01
View more
  1 in total

1.  Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.

Authors:  Yang Lo; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.